{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Machelart A"],"funding":["European Molecular Biology Organization","Agence Nationale de la Recherche","European Research Council","Fondation pour la Recherche M?dicale","FP7 Health","FP7 People: Marie-Curie Actions","R?gion Hauts-de-France","Institut Pasteur","European Regional Development Fund"],"pagination":["3992-4007"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6718168"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(4)"],"pubmed_abstract":["Multi-drug-resistant tuberculosis (TB) is a major public health problem, concerning about half a million cases each year. Patients hardly adhere to the current strict treatment consisting of more than 10 000 tablets over a 2-year period. There is a clear need for efficient and better formulated medications. We have previously shown that nanoparticles made of cross-linked poly-β-cyclodextrins (pβCD) are efficient vehicles for pulmonary delivery of powerful combinations of anti-TB drugs. Here, we report that in addition to being efficient drug carriers, pβCD nanoparticles are endowed with intrinsic antibacterial properties. Empty pβCD nanoparticles are able to impair Mycobacterium tuberculosis (Mtb) establishment after pulmonary administration in mice. pβCD hamper colonization of macrophages"],"journal":["ACS nano"],"pubmed_title":["Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis."],"pmcid":["PMC6718168"],"funding_grant_id":["ANR-16-CE35-0009","260872","608407","PTR22-16","PTR441","SPF20170938709","ANR-10-LABX-0035","12000080","12001407","ANR-14-CE08-0017","ANR-10-EQPX-04-01","260901"],"pubmed_authors":["Debrie AS","Deprez B","Willand N","Gref R","Giannini V","Muraille E","Menendez-Miranda M","Salzano G","Flipo M","Deboosere N","Nesslany F","Belhaouane I","Majlessi L","Villemagne B","Talahari S","Simar S","Demars A","Pancani E","Locht C","Brodin P","Brosch R","Li X","Hoffmann E","Jouny S","Baulard AR","Rouanet C","Machelart A"],"additional_accession":[]},"is_claimable":false,"name":"Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis.","description":"Multi-drug-resistant tuberculosis (TB) is a major public health problem, concerning about half a million cases each year. Patients hardly adhere to the current strict treatment consisting of more than 10 000 tablets over a 2-year period. There is a clear need for efficient and better formulated medications. We have previously shown that nanoparticles made of cross-linked poly-β-cyclodextrins (pβCD) are efficient vehicles for pulmonary delivery of powerful combinations of anti-TB drugs. Here, we report that in addition to being efficient drug carriers, pβCD nanoparticles are endowed with intrinsic antibacterial properties. Empty pβCD nanoparticles are able to impair Mycobacterium tuberculosis (Mtb) establishment after pulmonary administration in mice. pβCD hamper colonization of macrophages","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Apr","modification":"2025-05-31T23:14:10.78Z","creation":"2025-05-31T23:14:10.78Z"},"accession":"S-EPMC6718168","cross_references":{"pubmed":["30822386"],"doi":["10.1021/acsnano.8b07902"]}}